100 related articles for article (PubMed ID: 23775968)
21. Reply to S. Girnius et al.
Palladini G; Dispenzieri A; Gertz M; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
J Clin Oncol; 2013 Jul; 31(21):2750-1. PubMed ID: 24040662
[No Abstract] [Full Text] [Related]
22. Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival.
Tandon N; Muchtar E; Sidana S; Dispenzieri A; Lacy MQ; Dingli D; Buadi FK; Hayman SR; Chakraborty R; Hogan WJ; Gonsalves W; Warsame R; Kourelis TV; Leung N; Kapoor P; Kumar SK; Gertz MA
Bone Marrow Transplant; 2017 Aug; 52(8):1126-1132. PubMed ID: 28394369
[TBL] [Abstract][Full Text] [Related]
23. Treatment of AL amyloidosis with high dose therapy and autologous stem cell transplantation.
Dimopoulos MA
Leuk Lymphoma; 2006 Jun; 47(6):963-4. PubMed ID: 16840183
[No Abstract] [Full Text] [Related]
24. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis.
Cordes S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Kumar SK; Hogan WJ; Gertz MA
Cancer; 2012 Dec; 118(24):6105-9. PubMed ID: 22707405
[TBL] [Abstract][Full Text] [Related]
25. High-dose melphalan and autologous stem cell transplantation for AL amyloidosis: recent trends in treatment-related mortality and 1-year survival at a single institution.
Seldin DC; Andrea N; Berenbaum I; Berk JL; Connors L; Dember LM; Doros G; Fennessey S; Finn K; Girnius S; Lerner A; Libbey C; Meier-Ewert HK; O'Connell R; O'Hara C; Quillen K; Ruberg FL; Sam F; Segal A; Shelton A; Skinner M; Sloan JM; Wiesman JF; Sanchorawala V
Amyloid; 2011 Jun; 18 Suppl 1(Suppl 1):127-9. PubMed ID: 21838459
[TBL] [Abstract][Full Text] [Related]
26. [Light chain amyloidosis--clinical symptoms, update diagnosis, and treatment].
Charliński G; Jurczyszyn A; Wiktor-Jedrzejczak W
Przegl Lek; 2014; 71(2):102-9. PubMed ID: 25016786
[TBL] [Abstract][Full Text] [Related]
27. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
Sanchorawala V; Wright DG; Quillen K; Finn KT; Dember LM; Berk JL; Doros G; Fisher C; Skinner M; Seldin DC
Bone Marrow Transplant; 2007 Sep; 40(6):557-62. PubMed ID: 17589534
[TBL] [Abstract][Full Text] [Related]
28. Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology.
Hazenberg BP; Croockewit A; van der Holt B; Zweegman S; Bos GM; Delforge M; Raymakers RA; Sonneveld P; Vellenga E; Wijermans PW; von dem Borne PA; van Oers MH; de Weerdt O; Spoelstra FM; Lokhorst HM;
Haematologica; 2015 May; 100(5):677-82. PubMed ID: 25661441
[TBL] [Abstract][Full Text] [Related]
29. [Multisystemic amyloidosis in 2007].
Grateau G; Valleix S; Callard P
Rev Med Interne; 2007 May; 28(5):281-3. PubMed ID: 17291633
[No Abstract] [Full Text] [Related]
30. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
[TBL] [Abstract][Full Text] [Related]
31. Penile ulcers complicating systemic AL amyloidosis: a case report.
Arun M; Sloan SB; Shelton A; Sanchorawala V
Amyloid; 2016 Sep; 23(3):203-204. PubMed ID: 27187183
[No Abstract] [Full Text] [Related]
32. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate.
Gertz MA; Lacy MQ; Dispenzieri A; Ansell SM; Elliott MA; Gastineau DA; Inwards DJ; Micallef IN; Porrata LF; Tefferi A; Litzow MR
Bone Marrow Transplant; 2004 Dec; 34(12):1025-31. PubMed ID: 15516945
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis.
Morris KL; Tate JR; Gill D; Kennedy G; Wellwood J; Marlton P; Bird R; Mills AK; Mollee P
Intern Med J; 2007 Jul; 37(7):456-63. PubMed ID: 17547724
[TBL] [Abstract][Full Text] [Related]
34. Coexistence of primary AL amyloidosis and POEMS syndrome: efficacy of melphalan-dexamethasone and role of biochemical markers in monitoring the diseases course.
Adami F; Briani C; Binotto G; Altinier S; Tarantini G; Semenzato G
Am J Hematol; 2010 Feb; 85(2):131-2. PubMed ID: 20029992
[No Abstract] [Full Text] [Related]
35. Disappearance of immunoglobulins from persistent renal amyloid deposits following stem cell transplantation for heavy-and light-chain amyloidosis.
Safadi S; Saad A; Quint PS; Sethi S; Leung N; Kurtin P; Nasr SH
Nephrol Dial Transplant; 2015 Jul; 30(7):1151-5. PubMed ID: 25796445
[TBL] [Abstract][Full Text] [Related]
36. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease.
Casserly LF; Fadia A; Sanchorawala V; Seldin DC; Wright DG; Skinner M; Dember LM
Kidney Int; 2003 Mar; 63(3):1051-7. PubMed ID: 12631087
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation.
Herrmann SM; Gertz MA; Stegall MD; Dispenzieri A; Cosio FC; Kumar S; Lacy MQ; Dean PG; Prieto M; Zeldenrust SR; Buadi FK; Russell SJ; Nyberg SL; Hayman SR; Dingli D; Fervenza FC; Leung N
Nephrol Dial Transplant; 2011 Jun; 26(6):2032-6. PubMed ID: 21543655
[TBL] [Abstract][Full Text] [Related]
38. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.
Sanchorawala V; Seldin DC; Magnani B; Skinner M; Wright DG
Bone Marrow Transplant; 2005 Oct; 36(7):597-600. PubMed ID: 16044137
[TBL] [Abstract][Full Text] [Related]
39. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
Comenzo RL; Steingart RM; Cohen AD
N Engl J Med; 2008 Jan; 358(1):92; author reply 92-3. PubMed ID: 18175384
[No Abstract] [Full Text] [Related]
40. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
